Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
8
×
san francisco blog main
8
×
biotech
boston blog main
fda
national top stories
boston top stories
clinical trials
new york blog main
san diego blog main
san francisco
san francisco top stories
startups
boston
deals
new york top stories
raleigh-durham blog main
san diego top stories
seattle blog main
seattle top stories
acute myeloid leukemia
adverum biotechnologies
aimmune therapeutics
akili interactive labs
akouos
allergy
ambit biosciences
anaphylaxis
andrew oxtoby
astellas pharma
astellas pharmaceuticals
athena countouriotis
atlas venture
audentes therapeutics
avidity biosciences
biobucks
black diamond therapeutics
bladder cancer
bluebird bio
What
drug
8
×
therapeutics
8
×
medicines
cancer
ipo
approved
bets
biotech
fda
million
momentum
new
rare
therapy
treat
adding
affects
agency
ago
aimmune
allergy
americans
announced
approval
athena
awarded
backs
biotechs
black
boost
building
ceo
chief
click
clinic
companies
considering
countouriotis
data
date
Language
unset
Current search:
drug
×
" national blog main "
×
therapeutics
×
" san francisco blog main "
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
5 years ago
To Boost Cancer Pipeline, Gilead Bets at Least $50M on Startup Tango
@xconomy.com
5 years ago
TP Therapeutics Names New CEO, Gets $80M More For Cancer Drug Push
@xconomy.com
5 years ago
Sanofi Backs Click Therapeutics as Digital Medicines Gain Momentum
@xconomy.com
6 years ago
United Therapeutics Reaches $141M Deal for PAH Drug Firm SteadyMed